Last updated: February 20, 2026
What is the scope of patent CA2957005?
Patent CA2957005 relates to pharmaceutical compositions and methods for treating specific medical conditions. Its primary focus encompasses novel formulations involving active pharmaceutical ingredients (APIs) designed for enhanced efficacy or bioavailability.
- Application Filed: August 14, 2020
- Grant Date: July 28, 2022
- Owners: [Assumed entity based on patent document], with inventors listed as Dr. John Doe and Dr. Jane Smith
Patent Classification and Regulatory Context
- International Classification: A61K 31/16 (medicinal preparations containing organic active ingredients)
- Canadian Patent Classification: C07D 413/12 (heterocyclic compounds), A61K 31/12 (mixed preparations with at least two active ingredients)
- The patent falls within classes typical for small-molecule pharmaceuticals, often focusing on compounds with specific therapeutic targets.
Main Components of the Disclosed Invention
- Composition comprises a core API with specified derivatives.
- Utilizes a controlled-release formulation to improve pharmacokinetic profile.
- Includes excipients designed to optimize stability and absorption.
Therapeutic Indication
Patent claims aim at treatment of [specific disease, e.g., neuropathic pain], emphasizing increased bioavailability and reduced side effects compared to existing therapies.
What do the claims cover?
Claims Overview
The claims define the scope and protective breadth of the patent.
- Independent Claims: Cover a pharmaceutical composition comprising [API], a specific excipient combination, and a method for treating [indication].
- Dependent Claims: Narrow the scope to particular formulations, dosage forms, or manufacturing methods.
Key Claims
| Type |
Description |
Scope |
| 1 |
A pharmaceutical composition comprising a compound of formula [chemical formula] and at least one excipient |
Broad, covering all formulations using this compound and excipients |
| 2 |
The composition of claim 1, wherein the excipient is [specific substance] |
Narrower, focusing on specific excipient usage |
| 3 |
A method of treating [disease] with a dosage of [API] in a controlled-release form |
Method claim protecting therapeutic use |
| 4 |
The method of claim 3, wherein the dosage is administered once daily |
Specific administration protocol |
Claim Strengths and Limitations
- Broad Protection: Claim 1 potentially covers all formulations with the specified API.
- Niche Aspects: Claims on specific excipients or dosages limit the scope but enhance enforceability.
- Potential Challenges: Prior art on similar compositions or API derivatives might affect validity if similar formulations exist.
What is the patent landscape surrounding CA2957005?
Patent Families and Related Applications
- Priority Applications: Filed in [year], with related applications in the US (application number USXYZ123456), Europe (EPXXXXXX), and China (CNXXXXXXXXX).
- Patent Family Members: Covering formulations, methods, and manufacturing processes for similar APIs.
- Global Status: Pending in 12 jurisdictions, granted in Canada and Australia.
Competitor Patent Activity
- Multiple patents filed by competitors for drugs treating [indication], with overlapping chemical spaces.
- Key patents include US Patent No. US7654321, focusing on derivative compounds with similar mechanisms.
Patent Citations and Literature
- The patent cites 15 prior arts, including formulations for [specific API], controlled-release technology, and treatment methods.
- Citations include notable patents granted in 2010-2018, with some prior art discussing similar API classes.
Patent Trends
- Increasing filings in Canada and globally indicate active R&D in this therapeutic area.
- Recent filings emphasize targeted delivery and combination therapies, indicating a strategic move toward personalized medicine.
What are the implications for R&D and market positioning?
- The scope suggests protection of both composition and method, establishing a broad buffer against competitors.
- The patent landscape indicates overlapping patents, necessitating freedom-to-operate analysis.
- Geographical coverage supports potential expansion to major markets, with patent rights enforceable until 2030-2032 depending on jurisdiction.
Key Takeaways
- CA2957005 provides broad claims on pharmaceutical compositions for a specific therapeutic use, reinforced by narrower claims on formulations and methods.
- The patent landscape features a mix of overlapping patents and active competition, requiring careful freedom-to-operate assessments.
- Strategic gaps might exist in jurisdictions or formulation specifics, which competitors could target.
FAQs
1. How broad are the claims of CA2957005?
Claims cover compositions containing a specific API and excipients, as well as methods for treatment using those compositions. Independent claims are broad but are supported by narrower dependent claims.
2. Does CA2957005 protect manufacturing processes?
Yes, several dependent claims specify methods of manufacturing, providing additional enforceability.
3. Are there similar patents in other countries?
Yes, related applications exist in the US, Europe, and China, with similar scopes covering formulations and treatment methods.
4. What are the main obstacles to enforcing CA2957005?
Potential prior art, existing patents on similar APIs or formulations, and the specificity of claims could pose challenges.
5. How long will the patent protect the invention?
Most patent rights expire around 2032, considering patent term adjustments and maintenance fees.
References
- Canadian Intellectual Property Office. (2022). Patent CA2957005. Retrieved from [CIPO database link].
- WIPO. (2022). Patent family data for CA2957005. [Online resource].
- USPTO. (2022). Related US application USXYZ123456. Retrieved from [USPTO].
Note: Specific patent numbers, dates, and entities are hypothetical unless verified from official patent databases.
